Ibogaine for Opioid Addiction
& Detoxification

Medical Screening & Cardiac Clearance

Every opioid candidate undergoes a comprehensive pre-admission medical evaluation including full bloodwork panel, a 12-lead EKG with QTc interval measurement, hepatic and renal function assessment, and a thorough cardiac history review. Ibogaine is contraindicated in patients with QTc prolongation, structural heart disease, or significant cardiac arrhythmia risk. Candidates who do not achieve cardiac clearance are not admitted, and our medical team provides referral recommendations for alternative pathways.

Supervised Opioid Transition to Short-Acting Agents

Patients arriving on long-acting or lipophilic opioids, including fentanyl patches, methadone, buprenorphine, or extended-release formulations, undergo a supervised transition to short-acting opioids prior to ibogaine administration. This transition phase, conducted under daily medical supervision, depletes tissue-bound opioid reservoirs and creates the predictable pharmacokinetic profile required for safe and optimally effective ibogaine dosing. Fentanyl patients typically require a two- to three-day extended preparation period.

Custom Ibogaine Dosing Protocol

Our medical director designs an individualized ibogaine dosing protocol for each patient based on body weight, opioid substance and duration of use, hepatic metabolism parameters, degree of receptor neuroadaptation, and the clinical findings from pre-admission screening. Opioid detoxification protocols typically employ Ibogaine HCl for precision receptor-level dosing, with supplemental Total Alkaloid extract where deeper neuroplasticity support is clinically indicated. Dosing is never templated: it is calculated for the individual.

Treatment at MindScape Retreat with Continuous Monitoring

Ibogaine is administered in our medically-equipped, intimate sanctuary on Cozumel Island under continuous physician and nursing supervision for the duration of the treatment session and the 24-hour acute recovery period. Cardiac telemetry, pulse oximetry, and blood pressure monitoring are maintained throughout administration. The clinical environment is designed to minimize stimulation and support the inward-focused state that ibogaine induces, maximizing both safety and therapeutic depth.

Integration & 90-Day Aftercare

Opioid dependence is a chronic neurobiological condition that requires structured support beyond the detoxification event. Every patient departs with an individualized aftercare plan that includes referrals to integration-trained therapists, peer support program integration, scheduled clinical check-ins at 30, 60, and 90 days, and written guidance for managing cravings, environmental triggers, and the critical early-recovery period. This is why published studies pair ibogaine with structured aftercare.

Qualifying candidates are adults with a confirmed opioid use disorder diagnosis who are motivated to achieve detoxification. We treat patients dependent on fentanyl, heroin, oxycodone, hydrocodone, methadone, buprenorphine, and mixed opioid presentations. Medical exclusion criteria include significant cardiac disease or QTc prolongation, severe hepatic impairment, active psychosis, and certain medication interactions. The majority of opioid-dependent patients without cardiovascular contraindications are eligible for evaluation. Our team reviews each case individually and provides an honest assessment of candidacy.

Yes. Fentanyl's exceptional lipophilicity requires an extended preparation phase that distinguishes our fentanyl protocol from our standard opioid detoxification pathway. Fentanyl patients undergo a supervised transition to short-acting opioids over two to three days prior to ibogaine administration, depleting deep tissue fentanyl deposits and creating the pharmacokinetic predictability required for safe dosing. Total program length for fentanyl patients is typically 12 days rather than the standard 10. Every fentanyl guest is scored on COWS throughout that extended protocol, from admission through follow-up.

Methadone and buprenorphine (Suboxone) both require a medically supervised taper and transition prior to ibogaine administration. Methadone carries particular cardiac considerations due to its own QTc-prolonging properties and must be tapered to a low dose before ibogaine can be safely administered. Buprenorphine's partial agonist activity and high receptor affinity require a complete transition to short-acting opioids to avoid ibogaine's effects being blocked. Our medical team manages all transition protocols and determines admission timing based on confirmed pharmacokinetic clearance.

The ibogaine treatment itself interrupts the acute opioid withdrawal syndrome. Most patients experience a dramatic reduction in withdrawal symptoms, including nausea, muscle cramping, anxiety, and insomnia, within the first several hours of ibogaine administration. The noribogaine depot effect then maintains sub-threshold opioid receptor activity for four to six weeks post-treatment, providing a sustained buffer against acute withdrawal emergence. Some mild residual discomfort in the two to three days immediately following treatment is normal as the system restabilizes, but the severe acute withdrawal that characterizes unaided opioid detoxification is reliably interrupted.

Every patient departs with a written aftercare plan tailored to their opioid use history, social environment, and integration needs. This includes referrals to integration therapists and peer support programs in our clinical network, scheduled check-in calls with our clinical team at 30, 60, and 90 days post-treatment, craving management protocols and trigger-mitigation frameworks, and direct access to our medical director during the acute post-treatment window. For patients with co-occurring mental health diagnoses, aftercare plans include coordinated psychiatric follow-up. The structure of this aftercare framework is why published studies pair ibogaine with structured aftercare.